Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System

30 May 2020

Abstract excerpt

The successful implementation of chimeric antigen receptor (CAR)-T cell therapy in the clinical context of B cell malignancies has paved the way for further development in the more critical setting of acute myeloid leukemia (AML). Among the potentially targetable AML antigens, CD33 is insofar one of the main validated molecules. Here, we describe the feasibility of engineering cytokine-induced killer (CIK) cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to RNA Interference and Gene Delivery
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32526203
DOI: 10.1016/j.ymthe.2020.05.021

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon SystemPMID 32526203Read ↗

Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemiaSemantic proximity Read ↗

Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going?Semantic proximity Read ↗

Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantationSemantic proximity Read ↗

A new approach to gene therapy using <i>Sleeping Beauty</i> to genetically modify clinical‐grade T cells to target <scp>CD</scp>19Semantic proximity Read ↗

Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase SystemSemantic proximity Read ↗

Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapiesSemantic proximity Read ↗

Therapeutic immune cell engineering with an mRNA : AAV- <i>Sleeping Beauty</i> composite systemSemantic proximity Read ↗

Naturally occurring T cell mutations enhance engineered T cell therapies.Semantic proximity Read ↗

The tandem CD33-CLL1 CAR-T as an approach to treat acute myeloid leukemia.Semantic proximity Read ↗

Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations.Semantic proximity Read ↗

Transposon-mediated generation of CAR-T cells shows efficient anti B-cell leukemia response after ex vivo expansionSemantic proximity Read ↗

CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.